Wellbeing and mental health outcomes amongst hospital healthcare workers during COVID-19.

BACKGROUND: Global healthcare systems have been particularly impacted by the COVID-19 pandemic. Healthcare workers (HCWs) are widely reported to have experienced increased levels of baseline psychological distress relative to the general population, and the COVID-19 pandemic may have had an additive effect. However, previous studies are typically restricted to physicians and nurses with limited data available on hospital HCWs. We aimed to conduct a cross-sectional, psychological evaluation of Irish HCWs during COVID-19. METHODS: HCWs across five adult acute level-4 Dublin-based hospitals completed an online survey of wellbeing and COVID-19 experience. RESULTS: There were 1898 HCWs who commenced the survey representing 10% of the total employee base. The sample comprised nurses (33%), doctors (21%), Health and Social Care Professionals (HSCPs) (24%) and 'Other' disciplines (22%), and 81% identified as female. Clinical levels of depression, anxiety and PTSD symptoms were endorsed by 31%, 34% and 28% of respondents, respectively. Professional grouping effects included: nurses reporting significantly greater levels of COVID-19 exposure, infection, COVID-fear, moral injury, and post-traumatic distress; HSCPs were significantly less likely to report mood dysfunction. In terms of gender, males were significantly less likely to report negative pandemic experiences, low resilience, and significantly more likely to endorse 'minimal' depression, anxiety, and traumatic distress. Logistic regression modelling revealed mental health outcomes (depression, anxiety and PTSD symptoms) were associated with increased frontline exposure, fewer career years' experience, elevated pre-pandemic stress, and female gender. DISCUSSION: To our knowledge, this is the largest evaluation of psychological wellbeing amongst HCWs in acute hospitals in the Dublin region. Our findings have implications for healthcare workforce wellbeing and future service delivery.

Validation and psychometric evaluation of a brief screening questionnaire for psychological distress in patients with psoriasis.

BACKGROUND: Patients with psoriasis are at risk of a co-morbid diagnosis of depression and/or anxiety. It is therefore essential for dermatologists to have valid and effective instruments that can screen and monitor depression and anxiety symptoms in psoriasis patients. OBJECTIVE: The aim of this study was to validate the Mental Health Inventory (MHI-5) as a brief measure that can be used to evaluate psychological distress related to anxiety and depression in psoriasis patients. METHODS: The sample included 76 adult dermatological outpatients diagnosed with psoriasis. Participants completed the MHI-5, the Hospital Anxiety and Depression Scale (HADS) and six subscales of the Self-Compassion Scale (SCS). Confirmatory factor analysis (CFA) was applied to examine the factor structure of MHI-5. Convergent validity was examined by applying correlations among all measures. Discriminant validity was examined by applying hierarchical regression models. Reliability was examined by calculating Cronbach's alpha coefficient. RESULTS: Confirmatory factor analysis showed that the proposed one-factor model has a good fit to the data. The MHI-5 demonstrated satisfactory convergent validity by yielding significant moderate to strong correlations with the HADS and with the positive and negative subscales of the SCS. Discriminant validity was also evident with being at risk of anxiety predicting MHI-5 scores above and beyond the effect of gender and age. Hierarchical regressions were not performed because a very small number of participants (n = 3) were classified at risk of depression. The MHI-5 showed high internal consistency (α = 0.84). CONCLUSION: This investigation provided evidence that MHI-5 is a reliable and valid instrument that can be used to effectively capture psychological distress in psoriasis patients.

Myelomatous pleural effusion-A case report.

Multiple myeloma is a malignant proliferation of plasma cells, predominantly involving the bone marrow and skeletal system. Pleural effusions are rarely associated with multiple myeloma and most often signify a concurrent disease process, e.g. amyloidosis.(1,2) Malignant myelomatous pleural effusions are even more unusual, occurring in less than 1% of cases of multiple myeloma.(1) Here we report the case of a patient with multiple myeloma presenting with a myelomatous pleural effusion at disease recurrence.

Pre-donated autologous blood transfusion in scoliosis surgery.

We studied the use of autologous pre-donatedblood transfusion in surgery for scoliosis in 45 patients who were divided into two groups; 27 who pre-donated autologous blood (group 1) and 18 who were planned recipients of allogenic blood (group 2). Normovolaemic haemodilution and intra-operative blood salvage was used in six patients in group 1 and three patients in group 2. The two groups did not differ significantly with respect to age, American Society of Anaesthesiologists score, mean operative time, number of vertebral segments fused, total blood loss, length of stay in intensive care and length of stay in hospital. The risk of requiring allogenic blood transfusion was found to be significantly less in group 1 (7.4% v 88.9%, p < 0.001). Only 5.21% of autologous units were wasted. Although intra-operative blood salvage reduced the total blood loss in both groups, it did not affect the need for subsequent allogenic transfusion or reduce the number of pre-donated autologous units which were given (p < 0.67). Autologous blood transfusion requiredextra time, personnel, resources and cost pounds sterling 28.88 per patient more than allogenic transfusion, however, the projected costs at May 2002 make this programme cost-effective by pounds sterling 51.54 per patient. Pre-donated autologous blood transfusion is acceptable and safe in scoliosis surgery. It significantly reduces the subsequent requirement of allogenic transfusion. Although the cost is currently more than allogenic transfusion, with the increase in the costs of the latter and the decrease in potential donors which is anticipated, pre-donation of autologous blood will become comparatively cost-effective.

Masquerade syndrome: T-cell prolymphocytic leukemia presenting as panuveitis.

PURPOSE: To report a case of T-cell prolymphocytic leukemia with panuveitis as the primary presenting feature. METHODS: Case report. RESULTS: A 46-year-old woman presented with pain and blurred vision in the right eye. She was found to have signs of panuveitis with a central exudative retinal detachment. Further investigations revealed that she was suffering from the rare T-cell prolymphocytic leukemia. Both systemic and ocular manifestations of the disease resolved after chemotherapy with Campath-IH antigen and as she went into complete remission. The exudative detachment settled, and visual acuity recovered to 20/20. CONCLUSION: This case illustrates that leukemias can present with primarily ocular findings, and the sudden appearance of a serous retinal detachment with inflammatory signs in an otherwise healthy person warrants a thorough systemic screening for an underlying malignancy.

Modulation of resistance to ara-C by bryostatin in fresh blast cells from patients with AML.

Bryostatin has shown promise both as a cytotoxic agent and more recently as a modulator of 1-beta-D-arabinofuranosylcytosine (ara-C) resistance. This compound is currently in phase I and II trials as a single agent. We have used the 3-4,5-dimethylthiazol-2,5-diphenyltetrazolium bromide (MTT) assay as a means of investigating the direct effects of bryostatin and the effects of co-incubating this agent with ara-C on fresh blast cells from 53 patients with acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS). Additional studies evaluated the levels of accumulation and retention of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate (ara-CTP) in cells exposed to ara-C with and without bryostatin. Cells were exposed to bryostatin at a range of concentrations (0.1-100 nM) for 48 h and at 1 nM for both modulation studies and assessment of ara-CTP production. We found bryostatin to be cytotoxic in 18/58 (31%) tests whilst potentiation of formazan production in the MTT assay was seen in 21/58 (36%) patients. On co-incubation with bryostatin, 16/58 (27%) tests showed increased cytotoxicity to ara-C. Furthermore, there was a significant increase in the accumulation of ara-CTP on co-incubation with bryostatin (p = 0.0401). We found patients with in vitro resistance were more likely to become sensitised following exposure to bryostatin (p < 0.01). This study has emphasised the need to optimise treatment regimens for individual patients using this approach.

The clinical relevance of chemosensitivity testing in ovarian cancer.

The aim of this study was to assess the role of in vitro chemosensitivity testing in ovarian cancer using the MTT assay. Cells were separated from solid biopsy or ascitic fluid samples from 73 patients with ovarian adenocarcinoma, FIGO stage III to IV, on presentation. A 48 h drug exposure was followed by the MTT assay to determine sensitivity. Patients were treated by conventional regimens containing platinum. There was a marked variation in sensitivity to the platinum drugs between individual patients. Clinical data were available for 37 patients. Eleven out of seventeen (65%) patients in the sensitive group had a complete response to therapy, compared with 3 out of 20 (15%) in the resistant group (p = 0.005). The overall survival rates were 36% for the sensitive group compared with 18% for the resistant group (p = 0.37). This study suggests that chemosensitivity testing in ovarian cancer may be effective in improving initial clinical response.

The role of DNA topoisomerases II in drug resistance.

The essential nuclear enzyme DNA topoisomerase II is required for the action of a significant number of cytotoxic compounds. Resistance mechanisms identified in cell lines include down-regulation of protein expression, by gene methylation or down-regulation of mRNA, altered drug-DNA-protein interaction or ATP binding, post translational modification of the protein and alteration in expression of the isoenzymes. There is a lack of data relating the findings from these cell lines to observations from clinical practice and the evolution of specific drug resistance in patients. For leukaemias, several studies using different in vitro chemosensitivity assays show a correlation between the clinical response and the in vitro sensitivity (Sargent & Taylor, 1989; Pieters et al, 1989; Larsson et al, 1992; Bosanquet, 1991). From this data, outcome may be related to the mechanism of resistance and allow the development of strategies to overcome them. This includes the use of colony stimulating factors or antimetabolites or the development of new drugs to utilize topoisomerases as their target but which are not transported by P-glycoprotein. Thus an understanding of these mechanisms may help in the optimal use of the topoisomerase II inhibitors.